JW (Cayman) Therapeutics Co. Ltd (02126) submitted a monthly return for the period ended 31 October 2025 on 5 November 2025. The total authorized share capital remained at USD 50,000, representing 5,000,000,000 ordinary shares at a par value of USD 0.00001 each, with no changes during the period.

The number of issued ordinary shares stood at 416,473,250, unchanged from the previous month, and there were no treasury shares held. No new shares were issued during October 2025 from share options, warrants, or convertible instruments. The company maintained multiple share option schemes, including Pre-IPO and Post-IPO arrangements, but no exercises were recorded, resulting in zero changes to overall share capital.

The return confirms that all required regulatory steps have been followed in respect of the company’s share capital movements, with no alterations in issued shares or treasury shares during the reporting month.